We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




POC Hemometer Compared with Hematology Analyzer

By LabMedica International staff writers
Posted on 18 Apr 2019
The burden of anemia remains unacceptably high in sub-Saharan Africa. More...
It is linked to numerous life-threatening consequences like poor cognitive ability, diminished immunity and aggravated mortality.

To avert its effect, timely and accurate determination of hemoglobin concentration has been recognized. This has taken varied determination methods such as cyanmethemoglobin, use of copper II sulfate, automated hematology analyzers and point-of-care (POC) devices as the latest invention.

Medial Laboratory Scientists at Clarke International University (Kampala, Uganda) and their colleagues enrolled 402 participants, of these, 156 (38.8%) were male and 246 (61.2%) female. Participants had varied age categories, of whom 65 (16.2%) were 1 month–5 years, 42 (10.4%) were 5–11 years, 12 (3.0%) were 12–14 years, while 283 (70.4%) were 15 years and older. The average levels of Hb were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic participants, respectively.

Blood samples were assayed to estimate the hemoglobin (Hb) concentration using the TrueHb hemometer and Sysmex i3 hematology analyzer. Anemia was defined as Hb levels less than 11.0 g/dL, 11.5 g/dL and 12.0 g/dL for children aged 6–59 months, 5–11 years and 12–14 years, respectively. For adults, anemia was considered as Hb concentration less than 12.0 g/dL in non-pregnant women, 11.0 g/dL in pregnant women and 13.0 g/dL in males.

The team reported that the average Hb levels were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic patients, respectively. They found that 155 participants were anemic, giving an anemia prevalence of 38.6%. The mean difference of the TrueHb and Sysmex i3 assays was 2.222 ± 1.079, and the two devices did not show a difference in their measurements. Further, they showed a significant level of agreement and intraclass correlation coefficients. The sensitivity, specificity, positive and negative predictive values were 100 %, 51.01%, 55.16% and 100 %, respectively. The average performance turnaround time (TAT) for the TrueHb hemometer was 2.46 minutes.

The authors concluded that the TrueHb POC hemometer is an accurate POC for Hb estimation with a good performance agreement with the Sysmex i3 analyzer. This, coupled with its utility aspects, makes it a good diagnostic tool in a high anemia burden and low-resource setting. The study was published on April 1, 2019, in the Journal of Blood Medicine.

Related Links:
Clarke International University


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.